In this powerful documentary, Dr. Sandra Steingraber calls for a globally enforceable Precautionary Principle to ban any environmental toxins that are associated with the risk of #cancer. There are very similar and growing concerns around the relationship between environmental toxins such as #pesticides and neurodegenerative disorders like #Parkinson disease, #Alzheimer and amyotrophic lateral sclerosis (#ALS). It is important that we all bundle forces, to create a healthier living environment, and to prevent diseases from happening, rather than waiting for them to occur – thus leading to severe and avoidable disability, and to enormous treatment costs for society. To this end, I’m proud to say that we have initiated stimulating discussions with the Dutch Cancer Society (KWF) to bundle our forces. / Bas Bloem on LinkedIn –

EU-pesticidencommissie SCoPAFF: het goede, het slechte en het lelijke / PAN Europe –
Een vrij onbekende maar mogelijk schadelijke pesticide is aangetroffen in vier van de vijf onderzochte mensen / Scientias –
“Geen enkele boer zal nog gif spuiten als een biologisch alternatief voorhanden is” / m.standaard.be –
Keuringsdienst van Waarde helpt ons wéér uit de droom: ‘We worden belazerd’ / Veronica Superguide –

Uitgelicht: Has the time come to redefine Parkinson’s disease?
The diagnostic criteria for Parkinson’s disease require the presence of a combination of cardinal motor signs, collectively known as parkinsonism. However, the pathological processes of Parkinson’s disease begin many years before parkinsonism becomes apparent, and more than 60% of dopaminergic nigrostriatal neurons have already been lost when parkinsonism emerges. This advanced stage of pathology hinders the potential efficacy of disease-modifying interventions.
This issue of The Lancet Neurology features two new biological frameworks that aim to overcome this challenge: the neuronal a-synuclein disease integrated staging system (NSD-ISS) and the SynNeurGe criteria. The purpose of these frameworks overlap; both are classification systems that define disease subtypes, including the earliest phases that antedate clinically manifest parkinsonism. The NSD-ISS additionally proposes a staging system that rates the putative extent or severity of the disease in an individual. Both frameworks are based, in part, on the weighted sum of genetic risks, presence of pathological a-synuclein, and loss of dopaminergic neurons, but there are differences in how the classifications are operationalised (table). We welcome these new frameworks, as they offer exciting opportunities for research, but we also anticipate specific challenges.
Read further on Has the time come to redefine Parkinson’s disease? – The Lancet Neurology

Eén opmerking over 'Extra editie Glyfosaat 23 – Sacred Earth: Sunrise – Parkinson, verkeer en meer'